Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00

Summary by marketbeat.com
Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research report on Thursday.

4 Articles

marketbeat.commarketbeat.com
Center

Truist Financial Lowers Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $796.00

Truist Financial reduced their price target on shares of Regeneron Pharmaceuticals from $801.00 to $796.00 and set a "buy" rating for the company in a research report on Thursday.

Read Full Article
Seeking AlphaSeeking Alpha
Lean Right

Regeneron Pharmaceuticals Non-GAAP EPS of $9.47 beats by $0.57, revenue of $3.61B beats by $130M (REGN:NASDAQ)

Regeneron (REGN) Q1 earnings: EPS and revenue beat, Dupixent and EYLEA sales trends, new $3B buyback, and updated 2026 guidance—read more now.

·United States
Read Full Article
pharmaceutical-technology.compharmaceutical-technology.com
Reposted by
Pharmaceutical Business reviewPharmaceutical Business review

Regeneron Q1 2026 net income falls 10% to $727m

Regeneron Pharmaceuticals has reported GAAP net income of $727m for Q1 2026, down 10% from $809m in Q1 2025.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

Seeking Alpha broke the news in United States on Wednesday, April 29, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)

Similar News Topics

Tarrytown icon

Tarrytown

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal